Poncirin Inhibits Osteoclast Differentiation and Bone Loss Through Down-Regulation of NFATc1 In Vitro and In Vivo
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chun Kwang-Hoon | - |
dc.contributor.author | Jin Hyun Chul | - |
dc.contributor.author | Kang Ki Sung | - |
dc.contributor.author | Chang Tong-Shin | - |
dc.contributor.author | Hwang Gwi Seo | - |
dc.date.available | 2020-09-14T00:35:30Z | - |
dc.date.created | 2020-07-01 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78194 | - |
dc.description.abstract | Activation of osteoclast and inactivation of osteoblast result in loss of bone mass with bone resorption, leading to the pathological progression of osteoporosis. The receptor activator of NF-κB ligand (RANKL) is a member of the TNF superfamily, and is a key mediator of osteoclast differentiation. A flavanone glycoside isolated from the fruit of Poncirus trifoliata, poncirin has anti-allergic, hypocholesterolemic, anti-inflammatory and anti-platelet activities. The present study investigates the effect of poncirin on osteoclast differentiation of RANKL-stimulated RAW264.7 cells. We observed reduced formation of RANKL-stimulated TRAP-positive multinucleated cells (a morphological feature of osteoclasts) after poncirin exposure. Real-time qPCR analysis showed suppression of the RANKL-mediated induction of key osteoclastogenic molecules such as NFATc1, TRAP, c-Fos, MMP9 and cathepsin K after poncirin treatment. Poncirin also inhibited the RANKL-mediated activation of NF-κB and, notably, JNK, without changes in ERK and p38 expression in RAW264.7 cells. Furthermore, we assessed the in vivo efficacy of poncirin in the lipopolysaccharide (LPS)-induced bone erosion model. Evaluating the micro-CT of femurs revealed that bone erosion in poncirin treated mice was markedly attenuated. Our results indicate that poncirin exerts anti-osteoclastic effects in vitro and in vivo by suppressing osteoclast differentiation. We believe that poncirin is a promising candidate for inflammatory bone loss therapeutics. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 한국응용약물학회 | - |
dc.relation.isPartOf | Biomolecules & Therapeutics | - |
dc.title | Poncirin Inhibits Osteoclast Differentiation and Bone Loss Through Down-Regulation of NFATc1 In Vitro and In Vivo | - |
dc.title.alternative | Poncirin Inhibits Osteoclast Differentiation and Bone Loss Through Down-Regulation of NFATc1 In Vitro and In Vivo | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000563998700006 | - |
dc.identifier.doi | 10.4062/biomolther.2018.216 | - |
dc.identifier.bibliographicCitation | Biomolecules & Therapeutics, v.28, no.4, pp.337 - 343 | - |
dc.identifier.kciid | ART002596792 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85087168071 | - |
dc.citation.endPage | 343 | - |
dc.citation.startPage | 337 | - |
dc.citation.title | Biomolecules & Therapeutics | - |
dc.citation.volume | 28 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Chun Kwang-Hoon | - |
dc.contributor.affiliatedAuthor | Jin Hyun Chul | - |
dc.contributor.affiliatedAuthor | Kang Ki Sung | - |
dc.contributor.affiliatedAuthor | Hwang Gwi Seo | - |
dc.subject.keywordAuthor | Osteoclast | - |
dc.subject.keywordAuthor | Osteoporosis | - |
dc.subject.keywordAuthor | Poncirin | - |
dc.subject.keywordAuthor | RANKL | - |
dc.subject.keywordAuthor | JNK | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.